ArticleFrontiers in microbiology2025
Integrating procurement, prescription, and resistance data to strengthen antimicrobial stewardship: insights from a public health institution in India.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sustained and sub-optimal antimicrobial use drives antimicrobial resistance (AMR), a major health systems challenge in low- and middle-income countries (LMICs) such as India. This study examined the relationship between institutional antimicrobial procurement and outpatient prescribing patterns, and how these influence resistance trends identified through antibiotic susceptibility testing (AST) in a public community hospital. Methods: Data were collected from three sources: (i) procurement records (2018-2022), (ii) AST results from urine, pus, and stool samples (2023-2024), and (iii) outpatient prescriptions (2023-2024). Each dataset was analyzed individually and in an integrated framework to assess interrelationships between antimicrobial use and resistance. Results: Amoxicillin-clavulanate, ciprofloxacin, and doxycycline were among the most procured drugs, with Escherichia coli (urine) resistance rates of 53%, 87%, and 39%, respectively. The most frequently prescribed antimicrobials were Amoxicillin-Clavulanate (24%), Cefixime (15%), and Azithromycin (11%); over 50% were broad-spectrum agents and over 90% belonged to the WHO AWaRe "Access" category. Correlation analysis revealed a weak positive association between procurement and sensitivity, indicating that higher procurement did not necessarily increase resistance. Discussion: These findings demonstrate the feasibility of linking institutional datasets to identify inefficiencies in antimicrobial use and guide evidence-based stewardship interventions, including formulary revision, procurement alignment, and data-driven prescribing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.